AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for LAWRENCE B. PALMER
0.00 (0.00%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.51 - 5.75
52 week 2.92 - 9.32
Open 5.65
Vol / Avg. 0.00/606,133.00
Mkt cap 249.78M
P/E     -
Div/yield     -
EPS -0.63
Shares 44.45M
Beta 2.25
Inst. own 70%
Dec 10, 2015
AcelRx Pharmaceuticals Inc at Midtown CAP Summit Add to calendar
Dec 1, 2015
AcelRx Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 1:00PM EST - Add to calendar
Nov 19, 2015
AcelRx Pharmaceuticals Inc at Jefferies Global Healthcare Conference
Nov 11, 2015
AcelRx Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 3, 2015
AcelRx Pharmaceuticals Inc at �EBD BIO Europe- Fall
Oct 29, 2015
Q3 2015 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
Oct 29, 2015
Q3 2015 AcelRx Pharmaceuticals Inc Earnings Release
Oct 2, 2015
AcelRx Pharmaceuticals Inc Analyst & Investor Day - Webcast
Sep 29, 2015
AcelRx Pharmaceuticals Inc at Sachs Associates Biotech in Europe Investor Forum
Sep 15, 2015
AcelRx Pharmaceuticals Inc at EBD Group BioPharm America
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 32.86% -639.31%
Operating margin 46.05% -721.66%
EBITD margin - -705.06%
Return on average assets 20.84% -33.96%
Return on average equity 55.43% -55.67%
Employees 50 -
CDP Score - -


351 Galveston Drive
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 49
Bio & Compensation  - Reuters
Howard B. Rosen Interim Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 57
Bio & Compensation  - Reuters